Skip to main content

Table 3 Patients' characteristics and ART outcome according to the controlled ovarian stimulation protocol

From: Fertility preservation after gonadotoxic treatments for cancer and autoimmune diseases

Characteristics

GnRH antagonist

PPOS

P-value

Number of participants (n)

16

 

11

  

Number of cycles (n)

18

 

15

  

Age (years)

34

(30–37)

33

(32–35)

0.979

AFC

10

(5–19)

9

(6–15)

0.888

Basal FSH (IU/L)

6.1

(5.8–9.4)

6.1

(4.2–8.9)

0.663

AMH (ng/ml)

1.96

(1.32–4.77)

1.60

(0.99–3.65)

0.287

Disease type [n (%)]a

 Haematological cancers

2

(11.1)

0

(0.0)

 

 Breast cancer

13

(72.2)

8

(53.3)

 

 Gynecological cancers

2

(11.1)

2

(13.3)

 

 Sarcoma

0

(0.0)

0

(0.0)

 

 Other cancers

0

(0.0)

4

(26.7)

 

 Systemic autoimmune diseases

1

(5.6)

1

(6.7)

 

Stimulation start timing/ stimulation phase [n (%)]b

 Normal (Day 1–4)

13

(72.2)

5

(33.3)

 

 Random (Follicular phase, Luteal phase)

5

(27.8)

8

(53.3)

 

 DuoStim

0

(0.0)

2

(13.3)

 

Gonadotrophin

 Starting dose of Gonadotropin (IU)

150

(150–281)

225

(188–225)

0.498

 Duration of Gonadotropin use (days)

10

(8–10)

10

(9–12)

0.475

 Total dosage of Gonadotropin use (IU)

1800

(1369–2325)

2175

(1725–2700)

0.319

Triggar [n (%)]b

 hCG or recombinant hCG

16

(88.9)

14

(93.3)

 

 GnRHa

1

(5.6)

0

(0.0)

 

 Dual triggar

1

(5.6)

1

(6.7)

 

 Serum estradiol on trigger day (pmol/L)

1035

(762–1464)

681

(525–1404)

0.270

Outcome of oocyte retrieval

 Number of oocyte retrieved (n)

10

(6–15)

8

(5–11)

0.414

 Number of MII oocytes retrieved (n)

9

(4–11)

8

(5–10)

0.810

 Number of MI oocytes retrieved (n)

1

(0–1)

0

(0–1)

0.196

 Number of GV oocytes retrieved (n)

1

(0–1)

0

(0–0)

0.051

 Mature oocyte rate (%)c

86.7

(71.6–99.0)

100

(91.0–100)

0.052

Method for fertilisation [n (%)]b

 Conventional insemination

2

(11.1)

2

(13.3)

 

 Intracytoplasmic sperm injection

1

(5.6)

4

(26.7)

 

 Split

4

(22.2)

0

(0.0)

 

 None

11

(61.1)

9

(60.0)

 

Embryological outcome

 Fertilisation rate (%)d

60.0

(50.4–68.9)

87.5

(56.3–100)

0.374

 Cleavage developmental rate (%)e

71.4

(58.3–100)

100

(89.3–100)

0.237

 Blastocyst developmental rate (%)f

100

(70.8–100)

100

(87.5–100)

0.694

 Frozen embryo (n)

4

(3–4)

5

(2–6)

0.768

  1. Data are median (quartile) unless stated otherwise
  2. GnRH Gonadotrophin-releasing hormone, PPOS Progestin-Primed Ovarian Stimulation, AFC Antral follicle count, AMH Anti-Mullerian hormone, FSH Follicle stimulating hormone, LH Luteinizing hormone, hCG Human chorionic gonadotropin, GnRHa Gonadotrophin-releasing hormone analogue, MI/II Metaphase I/II, GV Germinal vesicle
  3. a / participants, b / cycles, c MII oocytes / retrived oocytes, d fertilised oocytes / MII oocytes, e 8-cells (> day3 6-cells) / fertilised oocytes, f Blastocysts / fertilised oocytes